Skip to content

Clinical study on the treatment of tracheotomy and pulmonary infection in stroke with phlegm-dampness-accumulation syndrome by the prescription of drying dampness, resolving phlegm and strengthening spleen

Clinical study on the treatment of tracheotomy and pulmonary infection in stroke with phlegm-dampness-accumulation syndrome by the prescription of drying dampness, resolving phlegm and strengthening spleen

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075654
Enrollment
Unknown
Registered
2023-09-12
Start date
2023-09-06
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tracheotomy and pulmonary infection in stroke

Interventions

Control group:Conventional comprehensive treatment
Treatment group:Conventional comprehensive treatment combined with the prescription of drying dampness, resolving phlegm and strengthening spleen

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years old; (2)Meet the diagnostic criteria for stroke in Western medicine; (3) Meet the diagnostic criteria for pulmonary infection in Western medicine; (4) Meet the diagnostic criteria for stroke in traditional Chinese medicine and the diagnostic criteria for the syndrome of phlegm-dampness accumulating in the lung; (5) Tracheotomy has been performed and a tracheal tube has been left in place; (6) Pulmonary infection after stroke and meeting the diagnostic criteria for pulmonary infection; (7) The patient's vital signs are basically stable, and the patient or family members agree to participate in the trial.

Exclusion criteria

Exclusion criteria: (1) Non Conformance the above inclusion criteria; (2) Patients with pulmonary infectious disease before stroke; (3) Brain diseases caused by brain injury, brain tumors, brain parasitic diseases, brain arteriovenous malformations, blood system diseases, etc.; (4) Patients with other systemic infectious diseases; (5) Patients with severe primary diseases such as heart, liver, kidney, endocrine and hematopoietic systems; (6) Pregnant or lactating women, or mental illness; (7) Patients who are allergic or have contraindications for the known drug components in this study.

Design outcomes

Primary

MeasureTime frame
Procalcitonin;C-reactive protein;Neutrophil to lymphocyte ratio;IL-6;Cytology and Etiology of Bronchial Alveolar Lavage Fluid ;Urinary metabolomics;Clinical pulmonary infection score;Scores of Traditional Chinese Medicine Syndrome Efficacy;The rating of extubation;Adverse reactions;Iung CT;

Countries

China

Contacts

Public ContactLI KAI

The First Affiliated Hospital of Guangxi Medical University

782721314@qq.com+86 134 7117 7707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026